Net cash used in operating activities | |
Investing activities: | |
Purchases of short-term investments | -234.49M |
Proceeds from the sale of short-term investments | 277.97M |
Purchases of property, plant and equipment | -4.31M |
Proceeds from land sold to BioMed | |
Reduction of cash due to deconsolidation of Regulus Therapeutics Inc. upon adoption of a new accounting standard | |
Acquisition of licenses and other assets | |
Purchases of strategic investments | |
Net cash (used in) provided by investing activities | |
Financing activities: | |
Proceeds from issuance of equity | 7.25M |
Proceeds from equipment financing arrangement | |
Principal payments on debt obligations | -5.43M |
Net cash (used in) provided by financing activities | |
Net (decrease) increase in cash and cash equivalents | |
Cash and cash equivalents at beginning of period | 128.8M |
Cash and cash equivalents at end of period | 84.28M |
Supplemental disclosures of cash flow information: | |
Interest paid | |
Income taxes paid | |
Supplemental disclosures of non-cash investing and financing activities: | |
Amounts accrued for capital and patent expenditures | |
Capitalized costs and financing liability associated with leased facility |